Tobacco Law Means Drug Sponsor Opportunities May Not Stop At Cessation
This article was originally published in The Tan Sheet
The tobacco control act prompts FDA to consider new indications - such as smoking reduction - for smoking cessation products, which could lead to new criteria for application approval
You may also be interested in...
Participants at an FDA workshop will consider issues that could influence whether the agency extends the use of nicotine-replacement therapies beyond the current 12-week indication
The U.K.'s harm reduction indication for a nonprescription nicotine replacement therapy inhaler could bode well for GlaxoSmithKline's request that FDA allow a similar change for NRT products in the U.S
Tobacco giant Reynolds American Inc.'s purchase of Swedish NRT firm Niconovum will put the company in the business of serving both smokers and quitters